ArticleJournal of rheumatic diseases2026
Short- and long-term sustained remission and the role of joint accumulation in early and very early rheumatoid arthritis: a real-world perspective.
Article in Journal of rheumatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Joint accumulation and sustained remission in early rheumatoid arthritis.Journal of rheumatic diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to identify predictors of short- and long-term sustained remission in early rheumatoid arthritis (eRA) and very early rheumatoid arthritis (veRA), and to assess their relevance within the joint accumulation model paradigm. Methods: This retrospective real-world cohort study included adult Colombian RA patients. Based on symptom onset, patients were classified as eRA (≤12 months) or veRA (≤3 months). Sustained remission was defined using Clinical Disease Activity Index (CDAI) thresholds maintained for ≥6 months (short-term) and ≥24 months (long-term). Predictors were identified using robust Poisson regression. Results: In eRA, short-term remission was more likely in antinuclear antibodies (ANA)-positive patients (risk ratio [RR] 3.29, 95% confidence intervals [CI] 1.38~7.83) and less likely in those with higher baseline Health Assessment Questionnaire (HAQ) (RR 0.48, 95% CI 0.29~0.78). Long-term remission was more frequent in males (RR 2.67, 95% CI 1.11~6.46) and in patients with lower baseline Simple Disease Activity Index (SDAI) (RR 0.92, 95% CI 0.85~0.99). In veRA, short-term remission was negatively associated with anti-citrullinated protein antibodies (ACPA) (RR 0.74, 95% CI 0.58~0.93), swollen joint count (RR 0.52, 95% CI 0.27~1.00), and patient global assessment (RR 0.61, 95% CI 0.40~0.93). Long-term remission was associated with higher rheumatoid factor levels (RR 1.76, 95% CI 1.20~2.56), lower tender joint counts (RR 0.71, 95% CI 0.55~0.92), and slower joint accumulation rates (RR 0.51, 95% CI 0.29~0.90). These findings were consistent among disease-modifying anti-rheumatic drug (DMARD)-naïve patients. Conclusion: Distinct predictors of remission in eRA and veRA underscore the need for stage-specific treatment strategies. Our findings provide real-world evidence supporting the joint accumulation model and highlight the potential to optimize outcomes through tailored time-sensitive interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.